Lupin yesterday announced the launch of Sevelamer Hydrochloride tablets, 800 mg, having received an approval from the US Food and Drug Administration (FDA). The product will be manufactured at Lupin’s facility in Nagpur, the company informed in a statement.
It said that Sevelamer Hydrochloride tablets, 800 mg is a generic equivalent of Renagel tablets, 800 mg of Genzyme Corporation.
Sevelamer Hydrochloride tablets, 800 mg had estimated annual sales of $75 million in the US (IQVIA MAT December 2021), the statement further said.